Advertisement

Topics

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

17:06 EDT 16 Apr 2019 | OncLive

Daratumumab was associated with low overall response rates in patients with relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1

Original Article: Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement